Royalty Report: Drugs, Pain, Pharmaceuticals – Collection: 2633


Curated Royalty Rate Report
Created On: 2020-07-15, Record Count: 12


This collection of transactions and supporting information was developed using our AI algorithm to curate similar royalty reports into a cohesive collection to support your licensing, transfer pricing or other transaction scenarios where documented royalty rates and/or deal terms are important.
Created On: 2020-07-15
Record Count: 12

Primary Industries

  • Drugs
  • Pain
  • Pharmaceuticals
  • Disease
  • Therapeutic

IPSCIO Report Record List

Below you will find the records curated into this collection.  This summary includes the complete licensed property description so that you can review and determine if this collection covers the topics, technology or transaction type that is relevant for your needs.  The full report will include all relevant deal data such as the royalty base, agreement date, term description, royalty rates and other deal terms.  For reference, here is a sample of a full IPSCIO curated royalty rate report: Sample Report

IPSCIO Record ID: 2633

License Grant
The companies announced pursuant to a strategic alliance, the initiation of a Phase I clinical trial program of second abuse resistant drug candidate, called PTI-202.
License Property
In connection with the acceptance by the FDA of the investigational new drug application, or IND, for PTI-202, the company made a milestone payment. In connection with this milestone, we made a milestone payment of an undisclosed amount to a third party, pursuant to our agreement with that third party. The company is obligated to reimburse us for costs, including milestones, we incur under our agreement with the third party, pursuant to our collaboration with the company.  We could also receive up to an additional $dollars in additional milestone payments in the course of clinical development of Remoxy and other abuse-resistant opioid pain killers under the strategic alliance. In addition, subject to certain limitations, the company is obligated to fund development expenses incurred by us related to Remoxy and other abuse-resistant opioid pain killers pursuant to the collaboration agreement. The company is obligated to fund the commercialization expenses of, and has the exclusive right to market and sell, drugs developed in connection with the strategic alliance.

IPSCIO Record ID: 2927

License Grant
The Licensor and Licensee announced the development of a new abuse-resistant prescription pain medication called PTI-721 under the strategic alliance effective December 2005. PTI-721’s patented formulation is specifically designed to resist common methods of prescription drug abuse or misuse. The Licensor submitted an Investigational New Drug Application, or IND, to the FDA for PTI-721 and initiated a Phase I clinical study with PTI-721 in August 2008.
License Property
During the quarter ended September 30, 2008, the Licensor received $20.0 million in cumulative milestone payments from the Licensee for achieving clinical and regulatory milestones under the strategic alliance.
Field of Use
The Licensee is obligated to fund the commercialization expenses of, and has the exclusive right to market and sell, drugs developed in connection with the strategic alliance.

IPSCIO Record ID: 3602

License Grant
Subject to the terms and conditions of this Agreement and further subject to the pre-existing non-exclusive license granted by the Licensor, the Licensor hereby grants to Licensee the following licenses under Licensor's Technology and Patent Rights and under Licensor's ownership interest in Joint Technology and Joint Patent Rights, which licenses shall be exercisable only as set forth in this Agreement or in the Collaboration Agreement and for the conduct of the activities required or permitted in the performance of Licensee's obligations and exercise of its rights thereunder.  Parties entered into a collaborative agreement to develop and commercialize the Licensee’s drug candidate Remoxy and other abuse-resistant opioid painkillers.
License Property
Remoxy, which is an abuse-resistant version of long-acting oxycodone, is an investigational drug in late-stage clinical development for the treatment of severe to chronic pain.  Licensor has worldwide exclusive rights to commercialize Remoxy and the other abuse-resistant opioid drugs that are developed pursuant to the collaboration, other than in Australia and New Zealand.

IPSCIO Record ID: 8453

License Grant
The Licensee is the exclusive, worldwide commercial partner, with the Licensor, for Remoxy (except as to Australia/New Zealand).
License Property
The Licensor's lead drug candidate is called Remoxy (oxycodone) Extended-Release Capsules CII.

Remoxy is an investigational drug with a unique, controlled release formulation of oxycodone for patients with moderate-to-severe chronic pain and is designed to discourage common methods of tampering associated with prescription drug misuse and abuse.

The Licensor is a biopharmaceutical company that develops novel drugs.

Field of Use
The rights grants apply to the medical industry.

IPSCIO Record ID: 6705

License Grant
In a modification to its strategic alliance for REMOXY® the Licensee and the Licensor have amended the terms on sales outside the United States. The Licensee has also gained certain undisclosed rights related to the development of other opioid products covered by the collaboration Agreement.
License Property
REMOXY® is a strong painkiller with a unique formulation designed to reduce potential risks of unintended use.

IPSCIO Record ID: 26587

License Grant
We have licensed exclusive, worldwide, development and commercialization rights under an Agreement.

Remoxy is formulated with our Oradur technology and incorporates several abuse-deterrent properties with the convenience of twice-a-day dosing. Oxycodone is also the active drug ingredient in OxyContin®, a brand name narcotic painkiller.  Remoxy is intended for patients with chronic pain. Remoxy is currently in Phase III trials.

Field of Use
The rights granted apply to the pain management industry.

IPSCIO Record ID: 1208

License Grant
The Licensor has entered into a License Agreement dated October 30, 2007 with the Licensee, to develop and commercialize, in the United States, Canada and Mexico, Acurox®, Acuracet® (oxycodone HCI/niacin/APAP) Tablets, Vycavert® (hydrocodone bitartrate/niacin/APAP) Tablets and a fourth undisclosed opioid analgesic product candidate utilizing our proprietary Aversion® Technology.
License Property
The Licensee has an option to License in the  territory all future opioid analgesic products developed utilizing Aversion® Technology. The Agreement provides that Licensor or Licensee may develop additional opioid analgesic product candidates utilizing our Aversion® Technology and, if Licensee exercises its option to License such additional product candidates, they will be subject to the milestone and royalty payments and other terms of the Agreement.

The drug is part of a class of opioid analgesic products for treatment for moderate to severe acute pain.

The Licensor is responsible, using commercially reasonable efforts, for all Acurox® Tablet development activities through FDA approval of a 505(b)(2) NDA, for which our expenses are reimbursed to us by the Licensee. After NDA approval the Licensee will be responsible for manufacturing and commercializing Acurox® Tablets in the U.S.

Field of Use
The rights granted apply to the pharmaceutical market.

IPSCIO Record ID: 260417

License Grant
This License agreement is pursuant to a certain Collaboration Agreement between the parties.

Licensor grants the following licenses under Licensors Technology and Licensors Patent Rights and under Licensors ownership interest in Joint Technology and Joint Patent Rights:

For Development, an exclusive license in the U.S. Territory, beginning immediately upon approval by the FDA of the NDA for each Product, to conduct Product Development with respect to such Product, and, in the ROW, beginning immediately following the initiation of Phase II clinical trials for each Product by Licensor in the U.S. Territory, to conduct Product Development with respect to such Product, in the Territory, to conduct Development on Remoxy, and in the Territory, to conduct Development on Products, exercisable only in the event that: Licensor suspends, closes or otherwise ceases to operate a majority of its business relating to this Agreement and the Collaboration Agreement, or in any case commenced by or against Licensor under the Bankruptcy Code, upon entry of an appropriate order or findings by the court presiding over such case, Licensor is in material breach of this Agreement or the Collaboration Agreement and such breach is not cured within sixty (60) days of the occurrence of the breach or Licensor rejects this Agreement or the Collaboration Agreement.

For Commercialization, an exclusive license in the Territory to Market, use, offer for sale, sell and import Products.

This agreement includes non-exclusive grants from Licensee to Licensor.

License Property
The Product means any dosage form of Remoxy,  an abuse-resistant opioid painkiller, and any other product in the Field that incorporates the SABER Technology and is covered by the rights licensed to Licensor under the DLA, the Development and License Agreement, dated as of December 19, 2002, and that is Developed or Marketed pursuant to the Collaboration Agreement.

REMOXY means a drug product in the Field that contains oxycodone as its opioid API and that is formulated using the SABER Technology.

SABER Technology means the pharmaceutical formulation technology and methods of use that are covered by the rights granted to Licensor pursuant to the DLA.

Field of Use
The Field means pharmaceutical formulations for use in humans that contain no more than one opioid API formulated using the SABER Technology, in accordance with the DLA.

IPSCIO Record ID: 5998

License Grant
The Licensor announced that it had entered into an amendment to the Amended and Restated Strategic Alliance Agreement, dated as of April 2, 2002, by and between the Licensee and the Licensor on the collaboration for Opana® ER (Opana is in a group of drugs called narcotic pain relievers.  It is similar to morphine.) (oxymorphone HCI) extended-release tablets CII. In addition to amending the royalty rates, Endo would pay Penwest a percentage of any subLicense income it receives and milestone payments in addition to other changes in the agreement.

IPSCIO Record ID: 282861

License Grant
The Parties agree to collaborate and Licensor will provide product development services including analytical methods development and validation and formulation of a generic pharmaceutical product in the Territory.  Licensee will be responsible for the payment of costs and expenses incurred by the Collaboration Parties in connection with the  active pharmaceutical ingredients.
License Property
Product means the drug product to be mutually agreed upon by the parties that is a generic equivalent of a synthetic narcotic analgesic drug product.

Licensor is engaged in the research and development of generic pharmaceutical products and has accumulated  considerable knowledge in the field of pharmaceutical product development management services.

Field of Use
Narcotic agents are potent analgesics which are effective for the relief of severe pain. Analgesics are selective central nervous system depressants used to relieve pain. The term analgesic means 'without pain'.

IPSCIO Record ID: 233488

License Grant
The Licensor and Chinese Licensee entered into an exclusive licensing agreement for the development and commercialization of Oliceridine in United States and China.
License Property
Oliceridine is a G protein biased ligand of the µ opioid receptor, for the management of moderate-to-severe acute pain where intravenous, or IV, administration is preferred.
Field of Use
Oliceridine is an opioid drug that is under evaluation in human clinical trials for the intravenous treatment of severe acute pain.

IPSCIO Record ID: 6647

License Grant
The Company entered into a License Agreement granting exclusive rights to develop and commercialize DM-1796 for pain indications in the United States, Canada and Mexico.
License Property
DM-1796 is for post-herpetic neuralgia.
Field of Use
In March 2010, the Licensee submitted a New Drug Application for DM-1796 to the U.S. Food and Drug Administration for the management of post-herpetic neuralgia.
Disclaimer: The information gathered from RoyaltySource® database was sourced from the U.S. Securities and Exchange Commission EDGAR Filings and other public records. While we believe the sources to be reliable, this does not guarantee the accuracy or completeness of the information provided. Further, the information is supplied as general guidance and is not intended to represent or be a substitute for a detailed analysis or professional judgment. This information is for private use only and may not be resold or reproduced without permission.